MicroPET imaging and transgenic models: A blueprint for Alzheimer's disease clinical research

Trends in Neurosciences

Volumn 37, Issue 11, 2014, Pages 629-641

  Zimmer, Eduardo R ^a,b,c   Parent, Maxime J ^a,b   Cuello, A Claudio ^d   Gauthier, Serge ^a,b   Rosa Neto, Pedro ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Amyloid; MicroPET; Neurodegeneration; Positron emission tomography; Radiopharmaceuticals

Indexed keywords

AMYLOID; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; TAU PROTEIN; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; CLINICAL RESEARCH; HUMAN; MICRO POSITRON EMISSION TOMOGRAPHY; MONITORING; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; TRANSGENIC MOUSE; ANIMAL; BRAIN; DISEASE MODEL; METABOLISM; PATHOLOGY; PROCEDURES; SCINTISCANNING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84909981848     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2014.07.002     Document Type: Review

References (135)

1. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
2. McGeer P.L., McGeer E.G. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 2013, 126:479-497.
3. Jack C.R., et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
4. Rowe C.C., et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
5. Jacobs A.H., et al. PET-based molecular imaging in neuroscience. Eur. J. Nucl. Med. Mol. Imaging 2003, 30:1051-1065.
6. McKhann G.M., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging - Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:263-269.
7. Dubois B., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734-746.
8. Roman G., Pascual B. Contribution of neuroimaging to the diagnosis of Alzheimer's disease and vascular dementia. Arch. Med. Res. 2012, 43:671-676.
9. Nichols L., et al. Imaging and in vivo quantitation of beta-amyloid: an exemplary biomarker for Alzheimer's disease?. Biol. Psychiatry 2006, 59:940-947.
10. Herholz K., Ebmeier K. Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol. 2011, 10:667-670.
11. Rowe C.C., Villemagne V.L. Brain amyloid imaging. J. Nucl. Med. 2011, 52:1733-1740.
12. 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. J. Nucl. Med. 2013, 54:880-886.
13. Scarmeas N., et al. APOE-dependent PET patterns of brain activation in Alzheimer disease. Neurology 2004, 63:913-915.
14. Ishii K., et al. Decreased medial temporal oxygen metabolism in Alzheimer's disease shown by PET. J. Nucl. Med. 1996, 37:1159-1165.
15. Foster N.L., et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007, 130:2616-2635.
16. Mosconi L., et al. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J. Alzheimers Dis. 2010, 20:843-854.
17. 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J. Nucl. Med. 2013, 54:1420-1427.
18. 18F]-T807. J. Alzheimers Dis. 2013, 34:457-468.
19. Maruyama M., et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013, 79:1094-1108.
20. Politis M., et al. Imaging of microglia in patients with neurodegenerative disorders. Front. Pharmacol. 2012, 3:96.
21. Maeda J., et al. In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. J. Neurosci. 2011, 31:4720-4730.
22. Gotz J., Ittner L.M. Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 2008, 9:532-544.
23. McGowan E., et al. Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol. Dis. 1999, 6:231-244.
24. de Calignon A., et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012, 73:685-697.
25. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
26. Vogt B.A., Paxinos G. Cytoarchitecture of mouse and rat cingulate cortex with human homologies. Brain Struct. Funct. 2014, 219:185-192.
27. Lu H., et al. Rat brains also have a default mode network. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:3979-3984.
28. Mathis C.A., et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg. Med. Chem. Lett. 2002, 12:295-298.
29. 18F-FDDNP binding. J. Nucl. Med. 2009, 50:1464-1470.
30. Yang L., et al. Brain amyloid imaging--FDA approval of florbetapir F18 injection. N. Engl. J. Med. 2012, 367:885-887.
31. US Food and Drug Administration GE beta-amyloid agent approved. J. Nucl. Med. 2013, 54:10N.
32. Clark C.M., et al. Use of florbetapir-PET for imaging beta-amyloid pathology. J. Am. Med. Assoc. 2011, 305:275-283.
33. Ikonomovic M.D., et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131:1630-1645.
34. Maia L.F., et al. Changes in amyloid-beta and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci. Transl. Med. 2013, 5:194re192.
35. 18F-AV-45 (Florbetapir F 18). J. Nucl. Med. 2010, 51:913-920.
36. 18F-labeled benzoxazole derivatives as potential positron emission tomography probes for imaging of cerebral beta-amyloid plaques in Alzheimer's disease. J. Med. Chem. 2012, 55:9136-9145.
37. 11C-labeled imidazo[2,1-b]benzothiazoles (IBTs) as PET tracers for imaging beta-amyloid plaques in Alzheimer's disease. J. Med. Chem. 2011, 54:949-956.
38. 18F-barbiturates are PET tracers with diagnostic potential in Alzheimer's disease. Chem. Commun. (Camb.) 2013, 49:792-794.
39. 11C]PiB in Alzheimer's disease postmortem tissue. Alzheimers Dement. 2013, 9:P22-P23.
40. Lim S., et al. A copper radiopharmaceutical for diagnostic imaging of Alzheimer's disease: a bis(thiosemicarbazonato)copper(II) complex that binds to amyloid-beta plaques. Chem. Commun. 2010, 46:5437-5439.
41. Jack C.R., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
42. 18F-FDG kinetics in patients with traumatic brain injury. J. Nucl. Med. 2004, 45:775-783.
43. 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J. Nucl. Med. 2004, 45:594-607.
44. 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J. Nucl. Med. 2012, 53:59-71.
45. 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J. Nucl. Med. 2008, 49:390-398.
46. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain 2011, 134:1089-1100.
47. Zhang W., et al. A highly selective and specific PET tracer for imaging of tau pathologies. J. Alzheimers Dis. 2012, 31:601-612.
48. Belhocine T.Z., Prato F.S. Transbilayer phospholipids molecular imaging. EJNMMI Res. 2011, 1:17.
49. 11C]PIB-PET study. Neurobiol. Dis. 2008, 32:412-419.
50. 18F-FDG. J. Nucl. Med. 2012, 53:37-46.
51. 11C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites in rats. Nucl. Med. Biol. 1994, 21:573-581.
52. 18F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain. J. Med. Chem. 2004, 47:2228-2235.
53. 11C-AC-5216: a novel PET ligand for peripheral benzodiazepine receptors in the primate brain. J. Nucl. Med. 2007, 48:1853-1861.
54. 11C-PBR28 standardized uptake values. J. Nucl. Med. 2013, 54:1320-1322.
55. Pazos M.R., et al. Role of the endocannabinoid system in Alzheimer's disease: new perspectives. Life Sci. 2004, 75:1907-1915.
56. 11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorg. Med. Chem. 2010, 18:5202-5207.
57. Pappata S., et al. In vivo imaging of neurotransmission and brain receptors in dementia. J. Neuroimaging 2008, 18:111-124.
58. 11C] Ro 15-1788 (flumazenil) in baboon and human during positron emission tomography studies. Eur. J. Drug Metab. Pharmacokinet. 1991, 16:141-152.
59. Hansen T.D., et al. The influence of inhalational anesthetics on in vivo and in vitro benzodiazepine receptor binding in the rat cerebral cortex. Anesthesiology 1991, 74:97-104.
60. Pascual B., et al. Decreased carbon-11-flumazenil binding in early Alzheimer's disease. Brain 2012, 135:2817-2825.
61. 11C]Methylpiperidin-4-yl propionate and positron emission tomography. J. Cereb. Blood Flow Metab. 2004, 24:600-611.
62. Hsiao K., et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
63. Sturchler-Pierrat C., et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:13287-13292.
64. Tomiyama T., et al. A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J. Neurosci. 2010, 30:4845-4856.
65. Mucke L., et al. High-level neuronal expression of Abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20:4050-4058.
66. Holcomb L., et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 1998, 4:97-100.
67. Savonenko A., et al. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol. Dis. 2005, 18:602-617.
68. Jankowsky J.L., et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 2004, 13:159-170.
69. Willuweit A., et al. Early-onset and robust amyloid pathology in a new homozygous mouse model of Alzheimer's disease. PLoS ONE 2009, 4:e7931.
70. Jimenez S., et al. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic. J. Neurosci. 2008, 28:11650-11661.
71. Blanchard V., et al. Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp. Neurol. 2003, 184:247-263.
72. Radde R., et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006, 7:940-946.
73. Flood D.G., et al. A transgenic rat model of Alzheimer's disease with extracellular Abeta deposition. Neurobiol. Aging 2009, 30:1078-1090.
74. Cohen R.M., et al. A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric abeta, and frank neuronal loss. J. Neurosci. 2013, 33:6245-6256.
75. Wyss-Coray T., et al. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature 1997, 389:603-606.
76. Wyss-Coray T., et al. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. 2001, 7:612-618.
77. Ongali B., et al. Transgenic mice overexpressing APP and transforming growth factor-beta1 feature cognitive and vascular hallmarks of Alzheimer's disease. Am. J. Pathol. 2010, 177:3071-3080.
78. Santacruz K., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481.
79. Yoshiyama Y., et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.
80. Lewis J., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001, 293:1487-1491.
81. Platt B., et al. Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1. PLoS ONE 2011, 6:e27068.
82. 11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2005, 32:593-600.
83. Kawarabayashi T., et al. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 2001, 21:372-381.
84. Maeda J., et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 2007, 27:10957-10968.
85. Higuchi M. Visualization of brain amyloid and microglial activation in mouse models of Alzheimer's disease. Curr. Alzheimer Res. 2009, 6:137-143.
86. Klunk W.E., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
87. 11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. PLoS ONE 2012, 7:e31310.
88. 18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition. Neurobiol. Aging 2012, 33:2561-2571.
89. Klunk W.E., et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 2005, 25:10598-10606.
90. 18F]FDDNP microPET imaging correlates with brain Abeta burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Abeta antibody treatment. Neurobiol. Dis. 2011, 43:565-575.
91. Schenk D., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
92. Wang Y.J. Alzheimer disease: lessons from immunotherapy for Alzheimer disease. Nat. Rev. Neurol. 2014, 10:188-189.
93. 18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013, 9:666-676.
94. Zimmer E.R., et al. In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals. Transl. Neurodegener. 2014, 3:6.
95. 18F-FDG PET. J. Nucl. Med. 2013, 54:1564-1569.
96. Nicolakakis N., et al. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J. Neurosci. 2008, 28:9287-9296.
97. Tong X.K., et al. Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits. J. Neurosci. 2012, 32:4705-4715.
98. Luo F., et al. Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease. Neurobiol. Aging 2012, 33:933-944.
99. 18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol. Imaging Biol. 2009, 11:236-240.
100. Martin-Moreno A.M., et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J. Neuroinflammation 2012, 9:8.
101. Bondolfi L., et al. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J. Neurosci. 2002, 22:515-522.
102. Heneka M.T., et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci. 2006, 26:1343-1354.
103. Sanabria-Diaz G., et al. Glucose metabolism during resting state reveals abnormal brain networks organization in the Alzheimer's disease and mild cognitive impairment. PLoS ONE 2013, 8:e68860.
104. Yuan S.M., et al. Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(DeltaE9) transgenic mouse models of Alzheimer's disease. Acta Pharmacol. Sin. 2011, 32:295-302.
105. Poisnel G., et al. Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease. Neurobiol. Aging 2012, 33:1995-2005.
106. Rapic S., et al. Imaging microglial activation and glucose consumption in a mouse model of Alzheimer's disease. Neurobiol. Aging 2013, 34:351-354.
107. Papadopoulos P., et al. Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-beta and cerebrovascular pathology. PLoS ONE 2013, 8:e68612.
108. Mirrione M.M., et al. A novel approach for imaging brain-behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator. Neuroimage 2007, 38:34-42.
109. Goertzen A.L., et al. NEMA NU 4-2008 comparison of preclinical PET imaging systems. J. Nucl. Med. 2012, 53:1300-1309.
110. 18F-FDG PET studies in mice. J. Nucl. Med. 2006, 47:999-1006.
111. Hildebrandt I.J., et al. Anesthesia and other considerations for in vivo imaging of small animals. ILAR J. 2008, 49:17-26.
112. 18F]FDG micro PET imaging study. Neuroimage 2009, 44:1074-1080.
113. 18F]FDG uptake in mouse brain and heart using small animal PET. Nucl. Med. Biol. 2004, 31:251-256.
114. Qin L., et al. Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J. Neurochem. 2002, 83:973-983.
115. Xie Z., et al. Peroxynitrite mediates neurotoxicity of amyloid beta-peptide1-42- and lipopolysaccharide-activated microglia. J. Neurosci. 2002, 22:3484-3492.
116. Liu B., Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 2003, 304:1-7.
117. Venneti S., et al. PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiol. Aging 2009, 30:1217-1226.
118. Benito C., et al. Cannabinoid CB2 receptors in human brain inflammation. Br. J. Pharmacol. 2008, 153:277-285.
119. Cagnin A., et al. In-vivo measurement of activated microglia in dementia. Lancet 2001, 358:461-467.
120. 11C]DAA1106. Psychiatry Res. 2012, 203:67-74.
121. Iyo M., et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 1997, 349:1805-1809.
122. Hanyu H., et al. Regional differences in cortical benzodiazepine receptors of Alzheimer, vascular, and mixed dementia patients. J. Neurol. Sci. 2012, 323:71-76.
123. Small G.W., et al. PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 2006, 355:2652-2663.
124. 18F-Labeled benzoxazole derivatives as potential positron emission tomography probes for imaging of cerebral beta-amyloid plaques in Alzheimer's disease. J. Med. Chem. 2012, 55:9136-9145.
125. Mosconi L., et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 2005, 64:1860-1867.
126. Bishop K.M., Wahlsten D. Sex and species differences in mouse and rat forebrain commissures depend on the method of adjusting for brain size. Brain Res. 1999, 815:358-366.
127. Jones T., Rabiner E.A. The development, past achievements, and future directions of brain PET. J. Cereb. Blood Flow Metab. 2012, 32:1426-1454.
128. Hume S.P., et al. Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. Eur. J. Nucl. Med. 1998, 25:173-176.
129. Johnson G. Neuropsychopharmacology: the fifth generation of progress, 5th edn. Aust. N. Z. J. Psychiatry 2003, 37:247-249.
130. Pike V.W. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol. Sci. 2009, 30:431-440.
131. Small Animal Imaging - Basics and Practical Guide 2011, Springer-Verlag. F. Kiessling, B.J. Pichler (Eds.).
132. Kim H.S., et al. A rat model of photothrombotic capsular infarct with marked motor deficit: a behavioral, histologic, and microPET study. J. Cereb. Blood Flow Metab. 2014, 34:683-689.
133. Seo E.H., et al. Whole-brain functional networks in cognitively normal, mild cognitive impairment, and Alzheimer's disease. PLoS ONE 2013, 8:e53922.
134. Parent, M., et al. Resting-state connectivity impairment in a rat model of Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 9, P29-P30.
135. Leon W.C., et al. A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. Journal of Alzheimer's disease: JAD 2010, 20:113-126.